Table 3.

ThrombomiR panel.

miRNA	Abundance in Platelets	Platelet Contribution to Plasma Levels	Suitability as (Platelet) Biomarker (Inter Alia)	Sources	Reference
miR-320a	**	***	Potential biomarker for arrhythmogenic cardiomyopathy	Platelets, endothelial cells, and cardiomyocytes	[27]
miR-223-3p	****	****	Reduced plasma levels in healthy donors and CVD patients in response to antiplatelet therapy	Platelets	[11]
miR-197-3p	*	***	Potential biomarker of CVD in patients with T2DM	Platelets	[28]
miR-191-5p	***	****	Reduced plasma levels in healthy donors and CVD patients in response to antiplatelet therapy	Platelets and endothelial cells	[11]
miR-150-5p	*	*	Reduced plasma levels in healthy donors and CVD patients in response to antiplatelet therapy	Platelets and leukocytes	[11]
miR-126-3p	***	***	Linked to occurrence of MI in the general population	Platelets and endothelial cells	[29]
miR-28-3p	*	***	Potential biomarker of pulmonary embolism	Platelets and cardiomyocytes	[30]
miR-27b-3p	**	***	Potential biomarker of severe atherosclerosis	Platelets and endothelial cells	[31]
miR-24-3p	***	***	Reduced plasma levels upon potent platelet inhibition in patients with T2DM	Platelets, endothelial cells, and vascular smooth muscle cells	[28]
miR-23a-3p	***	***	Potential biomarker of coronary artery disease	Platelets	[32]
miR-21-5p	***	***	Elevated plasma levels in patients with AMI and angina pectoris	Platelets, vascular smooth muscle cells, endothelial cells, and cardiomyocytes	[33]
miR-451a	***	-	-	Erythrocytes	-
miR-122-5p	-	-	-	Liver cells	-

The average abundance of the selected miRNAs in platelets was calculated using the qPCR data (Figure 2). The platelet contribution of the individual thrombomiRs to plasma levels was estimated based on the average rise from PPP to PRP (qPCR data, Figure 2). **** Very high, *** high, ** low, * very low, and - not detected/no platelet contribution.